Actavis plunks down $460M for U.K. generics specialist Auden Mckenzie

On an acquisition trail, U.S.-based Actavis ($ACT) has snapped up Auden Mckenzie, a U.K. generics maker, for £306 million in cash plus royalties. The deal, together with its $66 billion Allergan ($AGN) acquisition, will boost Actavis to the No. 1 slot in the U.K. pharma business. Auden Mckenzie will also add to Actavis earnings immediately, the company said. Release